Guillain-Barré syndrome: clinical profile and management
- Sreenivasa Rao Sudulagunta, Mahesh Babu Sodalagunta, Ranjitha Nidsale Sudarshan
- MedicineGerman medical science : GMS e-journal
- 21 September 2015
Seasonal occurrence predominantly in winter is noted and peak flow test may be a predictor of assessing requirement of mechanical ventilation and prognosis, and IVIG treatment is more expensive but is associated with less duration of hospital stay.
Biomarkers of Delirium Duration and Delirium Severity in the ICU*
- B. Khan, A. Perkins, M. Boustani
- Medicine, PsychologyCritical Care Medicine
- 26 November 2019
Interleukin-6, -8, and -10, tumor necrosis factor-α, C-reactive protein, and S-100β levels in quartile 4 were negatively associated with delirium-/coma-free days by 1 week and 30 days post enrollment, and in-hospital mortality was not found.
A systems biology approach to the global analysis of transcription factors in colorectal cancer
- M. Pradhan, N. Prasad, M. Palakal
- BiologyBMC Cancer
- 1 August 2012
A comprehensive text mining and computational methodology that focused on discovering new targets of one class of molecular entities, transcription factors (TF), within one particular disease, colorectal cancer (CRC), was developed.
S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit – an exploratory analysis
- B. Khan, M. Farber, M. Boustani
- Medicine, PsychologyInternational Journal of General Medicine
- 2 December 2013
This preliminary investigation identified a potentially novel role for S100β as a biomarker for delirium duration in critically ill patients and may have important implications for refining futureDelirium management strategies in ICU patients.
Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130
- S. Jalal, N. Hanna, L. Einhorn
- MedicineAmerican Journal of Clinical Oncology
- 1 August 2017
AMR and cyclophosphamide can be safely combined with little activity observed in heavily pretreated SCLC patients, and there was no correlation between topoisomerase IIA amplification or NQO1 polymorphisms and response.
A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma
- M. Robertson, Christopher W. Stamatkin, David Pelloso, J. Weisenbach, N. Prasad, A. Safa
- Medicine, BiologyJournal of immunotherapy
- 2018
A phase I study of recombinant human IL-18 given with ofatumumab was undertaken in patients with CD20+ lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation, finding no unexpected or dose-limiting toxicities were observed.
Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
- Sreenivasa Rao Sudulagunta, Mahesh Babu Sodalagunta, N. Prasad
- Medicine, BiologyGerman medical science : GMS e-journal
- 18 November 2015
A 50-year-old woman who was admitted initially with vomiting, hiccups and paraesthesias but was not diagnosed with NMO and presented with a severe progression of the disease was diagnosed to have autoimmune thyroiditis with lymphocytic infiltration of the thyroid which progressed from hyperthyroidism to hypothyroidism.
Phase I study of everolimus (E, RAD001) and ganitumab (G, AMG 479) in patients (pts) with advanced solid tumors.
- S. Jalal, R. Strother, E. Chiorean
- Medicine, Biology
- 20 May 2013
A phase I study to determine the safety, recommended phase II dose, pharmacokinetics, pharmacodynamics, and antitumor efficacy of E with G and found synergism between IGF and mTOR inhibitors has been documented preclinically.
Abstract P5-18-13: Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+ breast cancer
- K. Miller, Ce Steding, N. Prasad, L. Rojas, B. Herbert
- Medicine
- 15 December 2012
The combination of trastuzumab + imetelstat is well tolerated and results in decreases in HER2 phosphorylation similar to that seen in preclinical models.
Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC).
- M. Khawaja, A. Younger, E. Chiorean
- Medicine, BiologyJournal of Clinical Oncology
- 20 May 2011
The premise of this study is that administration of the IGF-1R inhibitor AMG 479 in conjunction with RAD001 would block this effect of mTOR inhibition, and therefore this drug combination will be clinically synergistic.
...
...